Quisel John D 4

What Happened

• John D. Quisel, CEO of Disc Medicine (IRON), exercised options and sold shares on June 18, 2026. He exercised 34,000 shares at $9.86 per share (exercise cost ≈ $335,240) and reported selling a total of 34,000 shares in open-market transactions for aggregate proceeds of ≈ $2,387,295.
• The sale transactions were effected under a Rule 10b5-1 trading plan adopted March 12, 2026. The filing also reports a separate derivative disposition of 34,000 shares at $0.00 (no proceeds); the filing notes the underlying options are fully vested.

Key Details

• Transaction date: June 18, 2026; Form filed June 23, 2026 (filed one business day after the 2-business-day Form 4 deadline for a June 18 trade).
• Exercise: 34,000 shares @ $9.86 (cost ≈ $335,240).
• Sales (open market): 22,927 shares @ weighted avg $69.92 (range $69.35–$70.33); 9,522 shares @ weighted avg $70.70 (range $70.36–$71.35); 1,551 shares @ weighted avg $71.61 (range $71.36–$71.85). Total sale proceeds ≈ $2,387,295.
• Additional line: 34,000-share derivative disposition reported at $0.00 (no proceeds); options are fully vested per the filing.
• Shares owned after transaction: not disclosed in the information provided.
• Notable footnotes: trades executed under a 10b5-1 plan (Footnote F1); weighted-average sale prices and price ranges provided (F2–F4); option vesting noted (F5).

Context

• The filing shows an option exercise paired with immediate open-market sales — a common sequence when insiders exercise options and sell shares to cover exercise costs or diversify. Purchases generally signal stronger insider conviction; this report documents option exercise and planned sales under a pre-established trading plan, not an ad hoc buy decision.